ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Janus kinase (JAK)"

  • Abstract Number: 1525 • 2018 ACR/ARHP Annual Meeting

    Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials

    Mamadaly Boudhabhay1, Thomas Barnetche2 and Pascale Vergne-Salle3, 1CHU de Limoges, Limoges, France, 2Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHU de Limoges, Limoges, France

    Background/Purpose: Recent studies comparing JAK-inhibitors (Jak-i) and adalimumab seem to show a better efficacy of JAK-i on patient-reported outcomes in rheumatoid arthritis (RA). As there…
  • Abstract Number: 2565 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

    Peter Nash1, Laura C. Coates2, Alan J. Kivitz3, Philip J. Mease4, Dafna D Gladman5, Jose A Covarrubias-Cobos6, Dona Fleishaker7, Cunshan Wang7, Elizabeth Kudlacz7, Sujatha Menon7, Lara Fallon8, Thijs Hendrikx9 and Keith S Kanik7, 1University of Queensland, Brisbane, Australia, 2University of Oxford, Oxford, United Kingdom, 3Altoona Center for Clinical Research, Duncansville, PA, 4Swedish Medical Center and University of Washington, Seattle, WA, 5Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 6Unidad Reumatologica Las Americas S.C.P, Mérida, Yucatan, Mexico, 7Pfizer Inc, Groton, CT, 8Pfizer Canada, Montreal, QC, Canada, 9Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the safety, tolerability, and efficacy of tofacitinib in…
  • Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting

    CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA

    Oliver Hendricks1, Stavros Chrysidis2, Jens Gerwien3, Chadi Saifan3, Francesco de Leonardis3, Pedro Lopez-Romero3, Jinglin Zhong4, Kevin Winthrop5 and Josef S. Smolen6, 1King Chr.Xs Rheumatology Hospital, Graasten, Denmark, 2Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, 3Eli Lilly and Company, Indianapolis, IN, 4Quintiles, Rockville, MD, 5Oregon Health Sciences University, Portland, OR, 6Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
  • Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials

    Michael Weinblatt1, Peter C. Taylor2, Gerd R. Burmester3, Chadi Saifan4, Chad D. Walls4, Maher Issa4, Terence P. Rooney4 and Tsutomu Takeuchi5, 1Brigham and Women’s Hospital, Boston, MA, 2Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, 3Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 4Eli Lilly and Company, Indianapolis, IN, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…
  • Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting

    Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab

    Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
  • Abstract Number: 1536 • 2018 ACR/ARHP Annual Meeting

    Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients

    Jon T. Giles1, Michael T. Nurmohamed2, Henry M. Rinder3, Venkatesh Krishnan4, Brenda J. Crowe4, Chadi Saifan4 and Thomas Dörner5, 1Columbia University, New York, NY, 2VU University Medical Center, Amsterdam, Netherlands, 3Yale University School of Medicine, New Haven, CT, 4Eli Lilly and Company, Indianapolis, IN, 5Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany

    Background/Purpose: Transient increases in circulating platelets were observed in patients with RA treated with baricitinib, an oral selective Janus kinase 1/2 inhibitor, approved for the…
  • Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting

    Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program

    Gustavo Citera1, Eduardo Mysler2, Hugo Madariaga3, Mario H Cardiel4, Oswaldo Castañeda5, Aryeh Fischer6, Pascal Richette7, Sandra Chartrand8, Jin Kyun Park9, Sander Strengholt10, Jose L Rivas11, Amit Thorat12, Tanya Girard13, Kenneth Kwok14, Lisy Wang15 and Dario Ponce de Leon16, 1Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Organización Médica de Investigación, Buenos Aires, Argentina, 3Clínica del Sur, Arequipa, Peru, 4Centro de Investigación Clínica de Morelia, Morelia, Mexico, 5Clínica Anglo Americana, Lima, Peru, 6Department of Medicine, University of Colorado, Denver, CO, 7Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, 8Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, 9Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 10Pfizer Inc, Capelle aan den IJssel, Netherlands, 11Pfizer SLU, Madrid, Spain, 12Pfizer Ltd, Mumbai, India, 13Pfizer Inc, Montréal, QC, Canada, 14Pfizer Inc, New York, NY, 15Pfizer Inc, Groton, CT, 16Pfizer Inc, Lima, Peru

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
  • Abstract Number: 1586 • 2018 ACR/ARHP Annual Meeting

    Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients

    María-José Barrera1,2, Sergio Aguilera3, Isabel Castro2, Patricia Carvajal2, Sergio González4, Claudio Molina1, Ulises Urzua2 and María-Julieta González2, 1Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, 2Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile, 3Reumatologia, Clinica Indisa, Santiago, Chile, 4Facultad de Odontología, Universidad Mayor, Santiago, Chile

    Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune epitheliitis that mainly affects the salivary and lachrymal glands. The glandular hypofunction has been associated to loss of…
  • Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting

    The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study

    Axel Finckh1, Christophe Tellenbach2, Almut Scherer2, Burkhard Moeller3, Adrian Ciurea4, Ines von Mühlenen5, Cem Gabay6, Diego Kyburz7, Ruediger Mueller8, Paul Hasler9 and Pascal Zufferey10, 1University Hospital of Geneva, Geneva, Switzerland, 2SCQM Foundation, Zurich, Switzerland, 3Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Rheuma-Basel, Basel, Switzerland, 6University Hospitals of Geneva, Geneva, Switzerland, 7Rheumatology, University Hospital Basel, Basel, Switzerland, 8Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, 9Kantonsspital Aarau AG, Aarau, Switzerland, 10Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland

    Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
  • Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting

    Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial

    Thomas Dörner1, Yoshiya Tanaka2, Michelle Petri3, Josef S. Smolen4, Ernst R. Dow5, Richard E. Higgs5, Robert J. Benschop5, Adam Abel5, Maria E. Silk5, Stephanie de Bono5 and Robert W. Hoffman5, 1Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 5Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
  • Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting

    Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor

    Mark C. Genovese1, Roy Fleischmann2, Bernard Combe3, Stephen Hall4, Ying Zhang5, Yijie Zhou5, Mohamed-Eslam F. Mohamed6, Sebastian Meerwein7 and Aileen L. Pangan5, 1Stanford University Medical Center, Palo Alto, CA, 2University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 3Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 4Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, 5AbbVie Inc., North Chicago, IL, 6Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

    Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
  • Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting

    Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs

    Philip J Mease1, Joel Kremer2, Stanley Cohen3, Jeffrey R Curtis4, Christina Charles-Schoeman5, Edward V Loftus6, Jeffrey D Greenberg7, Niki Palmetto8, Keith S Kanik9, Daniela Graham9, Cunshan Wang9, Pinaki Biswas8, Gary Chan10, Ryan DeMasi10, Hernan Valdez8, Thijs Hendrikx10 and Thomas V Jones10, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 3Metroplex Clinical Research Center, Dallas, TX, 4University of Alabama, Birmingham, AL, 5University of California, Los Angeles, CA, 6Mayo Clinic, Rochester, MN, 7Corrona, LLC, Southborough, MA, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
  • Abstract Number: 504 • 2017 ACR/ARHP Annual Meeting

    Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients

    Peter C. Taylor1, René Galien2, Annegret Van der Aa3, Corinne Jamoul3, Pille Harrison3, Chantal Tasset3, Yang Pan4, Lovely Goyal4, Wanying Li4 and Jacqueline Tarrant4, 1Kennedy Institute of Rheumatology, London, United Kingdom, 2Galapagos SASU, Romainville, France, 3Galapagos NV, Mechelen, Belgium, 4Gilead Sciences, Foster City, CA

    Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in active rheumatoid arthritis…
  • Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting

    Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)

    Hanna Kim1, Kristina M. Brooks2, Paul Wakim3, Mary Blake4, Stephen R. Brooks5, Gina A. Montealegre Sanchez6, Adriana Almeida de Jesus6, Yan Huang6, Wanxia Li Tsai7, Massimo G. Gadina4, Parag Kumar2 and Raphaela Goldbach-Mansky6, 1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 2Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, 3Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, 4Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, 5Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, 6Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, 7Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD

    Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
  • Abstract Number: 506 • 2017 ACR/ARHP Annual Meeting

    The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol

    Mohamed-Eslam F. Mohamed1, Sheryl Trueman1, Tian Feng2, Alan Friedman3 and Ahmed A. Othman2, 1Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, 2AbbVie, North Chicago, IL, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: Upadacitinib is a selective JAK1 inhibitor being developed for the treatment of several inflammatory diseases, including rheumatoid arthritis (RA).  Upadacitinib showed favorable efficacy and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology